US Pharmaceutical Imports Surge as Companies Stockpile Amid Trump Tariffs Threat

Strategic Insights -

The US imported a record $53 billion worth of pharmaceutical products and ingredients in March, a 160% increase from the same period last year, in anticipation of potential tariffs on the sector. This massive surge in imports underscores the impact of President Donald Trump's trade policies on global business, as companies rush to build stockpiles in the face of uncertainty. The pharmaceutical industry is bracing for a possible backlash, with US companies expanding domestic manufacturing and negotiations underway between the US and the UK to establish preferential tariff treatments.

Key Takeaways:

  • The US imported $53 billion worth of pharmaceutical products and ingredients in March, a 160% increase from the same period last year, according to the Census Bureau.
  • Companies such as Eli Lilly and Johnson & Johnson have announced plans to invest in domestic manufacturing, with a total of over $82 billion in investments.
  • Ireland accounted for $28 billion of the imports in March, up from $5.5 billion in the same period the previous year, due to the country's tax incentives and established pharmaceutical industry.
  • Several US pharmaceutical companies have manufacturing sites in Ireland, with about 50 US FDA-approved plants, making it a key location for the industry.
  • The impact of tariffs on the pharmaceutical sector could be cushioned by the import stockpiles built up by companies, according to JPMorgan Chase's Abiel Reinhart.
  • US companies such as Eli Lilly, Johnson & Johnson, and Biogen have established domestic manufacturing presence and processes to respond to volatile trade policy.

Statistics:

  • $53 billion: The record amount of pharmaceutical imports in March.
  • 160%: The increase in pharmaceutical imports in March compared to the same period last year.
  • $28 billion: The value of pharmaceutical imports from Ireland in March.
  • $5.5 billion: The value of pharmaceutical imports from Ireland in the same period the previous year.
  • $82 billion: Total investments in domestic manufacturing by US companies such as Eli Lilly and Johnson & Johnson.
  • 50: The number of US FDA-approved pharmaceutical plants in Ireland.
  • 2025: The year when Merck's inventory of the cancer drug Keytruda would last, according to CEO Rob Davis.

Sources:

  • The Financial Times.
  • The US Census Bureau.
  • JPMorgan Chase.